Healthcare Equipment and Supplies
Company Overview of Sera Prognostics, Inc.
Sera Prognostics, Inc., a biotechnology company, develops diagnostic and blood tests that help physicians to predict and manage preterm birth, preeclampsia, and other pregnancy complications. Sera Prognostics, Inc. has a strategic partnership with Agilent Technologies Inc. The company was founded in 2008 and is based in Salt Lake City, Utah.
2749 East Parleys Way
Salt Lake City, UT 84109
Founded in 2008
Key Executives for Sera Prognostics, Inc.
Co-Founder and Co-Chairman of The Scientific Advisory Board
Co-Founder and Co-Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Sera Prognostics, Inc. Key Developments
Sera Prognostics, Inc. Appoints Mansoor Raza Mirza to Its Board of Directors
Jan 7 15
Sera Prognostics, Inc. announced the appointment of Mansoor Raza Mirza to its Board of Directors. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshospitalet - the Copenhagen University Hospital, Denmark. He currently serves as a director of Karyopharm Therapeutics and Metamark Genetics. Dr. Mirza chairs the Health Ministry's obligatory teaching course on non-surgical treatment of cancer for Danish doctors specializing in Clinical Oncology. He is vice-president of the Danish Gynecologic Cancer Group (DGCG) and medical director of Nordic Society of Gynecologic Oncology (NSGO).
Sera Prognostics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM
Dec 23 14
Sera Prognostics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Gregory C. Critchfield, Executive Chairman, Chief Executive Officer and President.
Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health
Feb 12 13
Agilent Technologies Inc. and Sera Prognostics Inc. announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications. As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production. The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis. To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 7, 2014
May 30, 2014